

**Selexis Announces License Renewal with Diosynth Biotechnology**

**License Renewal Continues Diosynth Access to Selexis SURE Technology Platform™**

**for Rapid Development of High-Performance Mammalian Cell Lines**

**GENEVA, SWITZERLAND**, August 2, 2007/PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company offering technologies and services to enable significantly improved drug discovery, development, and cGMP production, announced today that it has executed a license renewal agreement with Diosynth RTP Inc. ("Diosynth"), allowing for Diosynth's continued access to the SURE Technology Platform, which includes the Selexis Genetic Elements™.

"We are pleased to renew this license agreement with Diosynth," said Dr. Igor Fisch, CEO of Selexis SA. Dr. Fisch added, "As a world class contract manufacturing organization, Diosynth readily appreciates the advantages and benefits of applying the Selexis SURE program for the rapid development of high-performance mammalian cell lines."

Under the terms of the license agreement, Diosynth will continue to have the right to use the SURE Technology Platform as well as receiving the latest improvements developed by Selexis over the recent months, enabling faster generation of mammalian cell lines. The financial details of the agreement were not disclosed.

**About Selexis:**

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enables significant improvements in the time, effort and costs required to develop and maintain high performance mammalian cell lines for use in the expression of pharmaceutically relevant proteins (i.e. targets, MABs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the **Selexis Genetic Elements™** using the **SURE Cell Line Development<sup>SM</sup>** process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

Selexis Genetic Elements™ and SURE Cell Line Development<sup>SM</sup> are trademarks of Selexis SA.

**MORE INFORMATION:**

**EUROPE**

Igor Fisch, Ph.D.  
41 (0)22 308 93 60  
igor.fisch@selexis.com

**UNITED STATES**

Andrew F. Sanford  
(617) 595-5769  
andrew.sanford@selexis.com